Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Irani

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
BJU International|November 22, 2008
One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsyRaphaël Briffaux, Patrick Coloby, Franck Bruyere, et al.
Urologia Internationalis|August 9, 2017
Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to ExpectDidier Jacqmin, Patrice Jichlinski, Laurent Molinier, et al.
European Urology|March 15, 2008
Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised studyJacques Irani, Olivier Celhay, Jacques Hubert, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 1, 2007
[Prognostic significance of "sawtooth" PSA and "stepwise" PSA]Olivier Celhay, Alexandre De La Taille, Laurent Salomon, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 6, 2004
[Neuroendocrine cancer of the prostate. A series of 6 cases]Xavier Breton, Caroline Plazanet, François Joseph Murat, et al.
Anti-Cancer Drugs|December 1, 2016
Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancerFrançois X Nouhaud, Jérome Rigaud, Fabien Saint, et al.
Presse Medicale (Paris, France : 1983)|March 5, 2013
[Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC)]Yann Neuzillet, Morgan Rouprêt, Stéphane Larré, et al.
Urology|March 23, 2005
Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detectionJacques Irani, Laurent Salomon, Michel Soulié, et al.
Human Pathology|April 12, 2013
8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomyGaelle Fromont, Julie Godet, Antoine Peyret, et al.
Scandinavian Journal of Infectious Diseases|April 4, 2002
Infective endocarditis after transrectal prostatic biopsyFrance Roblot, Moal Gwenaël Le, Jacques Irani, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
BJU International|November 22, 2008
One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsyRaphaël Briffaux, Patrick Coloby, Franck Bruyere, et al.
Urologia Internationalis|August 9, 2017
Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to ExpectDidier Jacqmin, Patrice Jichlinski, Laurent Molinier, et al.
European Urology|March 15, 2008
Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised studyJacques Irani, Olivier Celhay, Jacques Hubert, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 1, 2007
[Prognostic significance of "sawtooth" PSA and "stepwise" PSA]Olivier Celhay, Alexandre De La Taille, Laurent Salomon, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 6, 2004
[Neuroendocrine cancer of the prostate. A series of 6 cases]Xavier Breton, Caroline Plazanet, François Joseph Murat, et al.
Anti-Cancer Drugs|December 1, 2016
Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancerFrançois X Nouhaud, Jérome Rigaud, Fabien Saint, et al.
Presse Medicale (Paris, France : 1983)|March 5, 2013
[Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC)]Yann Neuzillet, Morgan Rouprêt, Stéphane Larré, et al.
Urology|March 23, 2005
Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detectionJacques Irani, Laurent Salomon, Michel Soulié, et al.
Human Pathology|April 12, 2013
8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomyGaelle Fromont, Julie Godet, Antoine Peyret, et al.
Scandinavian Journal of Infectious Diseases|April 4, 2002
Infective endocarditis after transrectal prostatic biopsyFrance Roblot, Moal Gwenaël Le, Jacques Irani, et al.
Pageof 12